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ABSTRACT.
Purpose: Compare patients treated for Retinopathy of Prematurity (ROP) in two
consecutive periods.
Methods: Retrospective inventory of anonymized neonatal and ophthalmological
data of all patients treated for ROP from 2010 to 2017 in theNetherlands, subdivided
in period (P)1: 1-1-2010 to 31-3-2013 and P2: 1-4-2013 to 31-12-2016. Treatment
characteristics, adherence to early treatment forROP (ETROP) criteria, outcome of
treatment and changes in neonatal parameters and policy of care were compared.
Results: Overall 196 infants were included, 57 infants (113 eyes) in P1 and 139 (275
eyes) in P2, indicating a 2.1-fold increase in ROP treatment. No differences were found
in mean gestational age (GA) (25.9  1.7 versus 26.0  1.7 weeks, p = 0.711), mean
birth weight (791  311 versus 764  204 grams, p = 0.967) and other neonatal risk
factors for ROP. In P2, the number of premature infants born <25 weeks increased by
factor 1.23 and higher oxygen saturation levels were aimed at in most centres. At
treatment decision, 59.6%(P1) versus 83.5%(P2) (p = 0.263) infantswere classified as
Type 1ROP (ETROP classification). Infants were treated with laser photocoagulation
(98 versus 96%) and intravitreal bevacizumab (2 versus 4%). Retreatment was
necessary in 10 versus 21 (p = 0.160). Retinal detachment developed in 6 versus 13
infants (p = 0.791) of which 2 versus 6 bilateral (p = 0.599).
Conclusion: Inperiod2,thenumberofinfantstreatedaccordingtotheETROPcriteria
(Type 1) increased, the number of ROP treatments, retinal detachments and retreat-
mentsdoubledandtheabsolutenumberofretinaldetachmentsincreased.Neonataldata
didnotprovideadecisiveexplanation,althoughchangesinneonatalpolicywerereported.
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Introduction
Retinopathy of prematurity (ROP) is a
sight threatening disorder caused by
abnormal retinal vessel development in
premature infants (Hellstrom et al.
2013). As more is known about the
pathological mechanisms, optimizing
the infant’s condition is warranted in
order to prevent the turning point to
severe and potentially blinding ROP.
However, neonatal risk factors cannot
always be completely controlled, and
therefore, timely ophthalmic screening
and treatment remain essential. In the
Netherlands, changes possibly influenc-
ing the development of severe ROP
were debated as paediatric ophthalmol-
ogists had the impression that since
several years, the number of infants
developing severe ROP had increased.
Certain factors might have contributed
to this development. First, following a
nationwide ROP inventory called the
NEDROP study (2009), a new Dutch
ROP guideline was implemented in
April 2013, in which the screening
inclusion criteria were altered (van
Sorge et al. 2014; van Sorge et al.
2014). This revision would reduce the
number of eligible infants by almost
one third, without missing treatment
warranting ROP (van Sorge et al.
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2013). Secondly, in the same guideline,
the early treatment for ROP (ETROP)
criteria was emphasized (Good 2004),
as the NEDROP study showed that
they were not yet widely implemented
in the Netherlands: in almost a fourth
of infants treated for ROP, no classi-
fication could be made into type 1 or 2
ROP. Overall, adherence to the
ETROP protocol implicates treatment
in earlier stages, which could conse-
quently result in an increase in the
number of infants requiring ROP treat-
ment. Moreover, changes in neonatal
care might have increased the risk for
severe ROP since the NEDROP study.
In 2010, the age limit of admitting and
actively treating premature infants in
Dutch neonatal intensive care units
(NICUs) was lowered from 25.0 to
24.0 weeks of gestation. Furthermore,
following the Neonatal Oxygenation
Prospective Meta-analysis (NeOProM,
2014) (Saugstad & Aune 2014), higher
oxygen saturation (SaO2) levels during
the first weeks of life were implemented
in most Dutch NICUs. This adjust-
ment warrants better survival but also
increases the risk for severe ROP
(Askie et al. 2017).
The aim of this study was to inves-
tigate changes in the prevalence and
characteristics of infants requiring
ROP treatment in the Netherlands
since the implementation of the new
Dutch ROP guideline in 2013. Further-
more, treatment characteristics and
anatomical outcome of ROP treatment
were investigated.
Materials and methods
The present study was initiated and
coordinated by the Leiden University
Medical Center. Data of infants treated
for ROP were retrospectively obtained
from patient files from all Dutch
NICUs. All data were delivered deper-
sonalized and coded using randomly
assigned numbers; therefore, informed
consent was not required according to
the General Data Protection Regula-
tion (GDPR) (GDPR 2016) and the
local medical ethical committee. Upon
inclusion, patients were categorized
into period 1 (old guideline): treated
from 1 January 2010 until 31 March
2013 (duration of inclusion of
39 months) and period 2 (new guide-
line): from 1 April 2013 until 31
December 2016 (45 months). The pri-
mary outcome is the number of treated
infants per group. Subsequently, the
number of treatments was compared to
the premature birth rate in the same
period. National birth numbers were
obtained from the Dutch neonatal
registry platform, Perined. Data of
the participating hospitals were com-
pared for birth rate, number of ROP
treatments, retreatments and outcome,
with preservation of individual privacy.
Infants treated in period 1 (from 1
January 2010 until 31 March 2013)
were treated according to the old
guideline, which advised screening
infants with a GA <32.0 weeks and/or
BW <1500 g. From 1 April 2013 (pe-
riod 2), the Dutch ROP screening
guideline recommends screening neo-
nates with GA <30.0 weeks and/or BW
<1250 and a selection of infants with
GA 30.0–32.0 weeks and/or BW 1250–
1500 g with presence of one or more of
the following risk factors: mechanical
ventilation (MV), sepsis, necrotizing
enterocolitis (NEC), administration of
postnatal glucocorticoids or hypoten-
sion treated with inotropic agents. For
ROP treatment, classification accord-
ing to the ETROP is used, which
advises treatment of so called type 1
ROP (Good 2004). However, in the
Netherlands ROP stage 2+ in zone II is
only treated when plus disease is pro-
gressive. The participating hospitals
were asked to indicate if the SaO2
policy was adjusted during the study
period and if so, what targets are used.
Neonatal data were obtained on gen-
der, GA, BW and the presence of
relevant risk or protective factors for
ROP being: multiple birth, sepsis (de-
fined as clinically ill with positive blood
cultures), intraventricular haemorrhage
(IVH, according to the classification of
Levene et al. (1982) or periventricular
leukomalacia (PVL, according to the
classification of de Vries et al. (1992),
presence of a treated patent ductus
arteriosus (PDA), infant respiratory
distress syndrome (IRDS), bron-
chopulmonary disease (BPD, defined
as oxygen dependency at 36.0 weeks
post-menstrual age (PMA)), NEC with
perforation, hyperglycaemia
(>8.0 mmol/L), twin-to-twin transfu-
sion syndrome (TTTS), hypotension
treated with inotropic agents, duration
of NICU admission >28 days, MV
>7 days, oxygen administration
>28 days, treatment with packed red
blood cells, treatment with inhaled
nitric oxide (iNO) and pre-and
postnatally administered glucocorti-
coids. Data to evaluate details of
treatment consisted of PMA, postnatal
age (PNA) at time of treatment deci-
sion and treatment, and maximum
zone and stage of ROP. Retinopathy
of Prematurity (ROP) was classified
according to the Revised International
Classification of Retinopathy of Pre-
maturity (2005) and categorized into
type 1 or 2 ROP according to ETROP
criteria (2005). Furthermore, charac-
teristics of treatment and possible
retreatments were evaluated. Eventu-
ally anatomical outcome, that is, reti-
nal detachment (RD) was recorded.
Statistical analyses
Statistical analyses were performed
using SPSS Statistics software version
23.0 IBM Corp., Armonk, N.Y., USA.
For quantitative variables, we used
number (n), mean (standard deviation
(SD)) and medians (ranges). For cate-
gorical variables, proportion (%) was
reported. P-values for continuous vari-
ables were calculated by using Mann–
Whitney U-test. In case of categorical
and/or binary variables, the Pearson’s
Chi-Square test or Fischer’s Exact test
was used. To correct for the difference
in inclusion periods (period 1:
39 months versus period 2:
45 months), a correctional factor was
used (45/39 = factor 1.15).
Results
During the seven-year study period,
data of 196 treated infants from 10
hospitals were obtained. Period 1
counted 57 infants (113 eyes), period
2: 139 infants (275 eyes) (Table 1). The
prevalence of ROP treatment in the
group of infants born in the Nether-
lands with GA <32.0 weeks was 1.1%
(57/5276) in period 1 and 2.3% (139/
6019) in period 2 (Fig. 1), representing
a 2.1-fold increase since the implemen-
tation of the new guideline.
Comparing national birth rates
between the two inclusion periods, the
number of newborns with GA 25.0–
<28.0 and 28.0–<32.0 weeks remained
relatively stable. However, the group of
infants with GA <25.0 weeks increased
by nearly one fourth (Fig. 1 and
Table 1). The range of live births,
defined as all live births excluding
neonatal death (<28 days after birth),
among the 10 participating hospitals is
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shown in Fig. 2. In the overall study
group, mean GA and BW were
25.9  1.7 weeks and 771  240 g,
respectively. Mean GA was similar
between the two treatment groups (pe-
riod 1: 25.9  1.7 weeks, period 2:
26.0  1.7 weeks (p = 0.711)) as well
as mean BW (period 1: 791  311 and
period 2: 764  204 g (p = 0.967)). No
statistically significant differences were
found in the prevalence of neonatal
risk factors (Table 2). All NICUs
implemented the NeOProM SaO2 cri-
teria since their publication; however,
one hospital adapted a slightly lower
and broader range (85–93%).
At treatment decision, 150 infants
(period 1: 34, period 2: 116) were
categorized as type 1 ROP, four (pe-
riod 1: 1, period 2: 3) as type 2 ROP
and 42 (period 1: 22, period 2: 20) did
not meet the ETROP criteria or could
not be classified due to missing data
(Table 3). Mean overall age at treat-
ment decision was 36.7  2.5 weeks
and comparable between the two
groups (Table 4). Retinopathy of Pre-
maturity (ROP) stage 3 or higher was
found in 49.1% of infants in period 1
versus 57.6% in period 2 (p = 0.144).
Between the participating hospitals,
median proportion of infants with
ROP stage ≥3 at treatment decision
was 57% with an interquartile range of
35% (range 20–90%).
Treatment was performed by ten
ophthalmologists in seven hospitals.
Overall, laser photocoagulation of the
retina was the predominant modality
of primary treatment (97.0%), six
infants received intravitreal Beva-
cizumab (IVB) (4 bilateral, 2 unilateral)
of which five in period 2. Apart from
one infant in period 1 and three infants
in period 2, all patients were lasered
bilaterally. Mean follow-up age was
31.5  24.3 months in period 1 and
13.3  12.6 in period 2. Overall, fol-
lowing primary treatment, ROP
recurred within 21  13 days and was
retreated in 31 patients (15.8%) (period
1: 10 (17.5%), period 2: 21 (15.1%)
p = 0.160). Retreatment characteristics
are described in Table 4.
Progression into retinal detachment
(RD, ROP stage 4 or 5) occurred in 19
(9.7%) patients of which 8 bilateral (2
versus 6, p = 0.599). Mean PMA at
first treatment was higher in the RD
group but did not reach statistical
significance (p = 0.743). Considering
other risk factors and treatment char-
acteristics, these groups were compara-
ble. Of the laser-treated infants, 18/190
(9.5%) versus one of six (16.7%)
primarily IVB-treated infants devel-
oped retinal detachment (p = 0.462).
Treatment characteristics and the
occurrence of risk factors did not differ
statistically significant comparing
infants developing RD to those that
did not. The highest treatment and
Table 1. Number of live births in the Nether-
lands according to gestational age for period 1
and period 2, and the increment corrected for





n = 139 Increment
28.0–<32.0 3927 4368 0.97
25.0–<28.0 1159 1383 1.03
<25.0 190 268 1.23
12.7…
10.2 13.6 19.1 16.9 6.5 18.1




























Births GA <25.0 Treated GA <25.0 Births GA 25.0 - <28.0 Treated GA 25.0 - <28.0 Births GA 28.0 - <32.0 Treated 28.0 - <32.0
Fig. 1. Annual live births according to gestational age in weeks at birth (pattern filled) and number of treatments (solid filled). Labels represent the
percentage of treated infants in the corresponding age category.
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retreatment rates were found in centres
where the youngest infants were born.
The percentage of recurrence varied
between 10.0% and 37.5% and RD
between 1.8 and 15.6% (ranges shown
in Fig. 3).
Discussion
This study investigated the number and
characteristics of infants treated for
ROP and the results of ROP treatment
in the Netherlands from 2010 to 2017.
Since the implementation of the new
Dutch ROP guideline in 2013, the
number of treatments and infants
developing retinal detachment due to
ROP has more than doubled. The
increase in our study corresponds to
the increase reported in the United
Kingdom, Sweden, Denmark and Aus-
tralia (Hameed et al. 2004; Todd et al.
2007; Slidsborg et al. 2008; Painter
et al. 2015; Holmstrom et al. 2018).
Several aspects could be considered to
explain this development.
First, the number of infants who,
based on gestational age (GA) at birth,
are at particular risk for (severe) ROP
has notably increased since 2013. While
the overall number of newborns with
GA <32.0 weeks, the age most
screening guidelines use as cut off point
for screening, remained stable, the
subgroup with GA <25.0 weeks
increased by nearly one-fourth. This
can be explained by a significant
change in neonatal policy. Compared
to other countries, Dutch neonatolo-
gists maintained a relatively restrictive
policy on active neonatal intensive care
treatment of extremely premature born
infants, because of the particularly
poor survival and increased morbidity
in even younger infants (Pignotti 2008;
Ishii et al. 2013; Guillen et al. 2015; De
Leeuw et al. 2000). In 2010, however,
this threshold was lowered from GA
25.0–24.0 weeks, as a similar incidence
of severe disabilities was demonstrated,
compared to those with GA 25.0 weeks
(de Laat et al. 2010). The observed
increase in number in this group (Fig. 1
and Table 1) suggests that the policy
change only gradually showed effect
since 2013 (41% increase from 190 in
period 1 to 268 in period 2) which is of
particular interest for our study.
Nonetheless, the absolute amount is
relatively small and consequently did
not reach statistical significance. More-
over, a recent inventory on the 2-year
follow-up of infants born at 24.0 weeks
showed no significant difference in the
occurrence of severe ROP (stage ≥ 3)
compared to infants born at
25.0 weeks of GA (Aarnoudse-Moens
et al. 2017). Thus, it seems more likely
that the increase in extremely prema-
ture infants in period 2 could only
partially explain the increase in ROP
treatment.
Another factor potentially contribut-
ing to the increase in treatment of ROP
was the introduction of higher oxygen
saturation levels in most Dutch NICUs
following the NeOProM meta-analysis
(Saugstad & Aune 2014). It is hypoth-
esized that the adoption of higher SaO2
in the first phase of ROP increases the
risk for the development of treatment



























Fig. 2. Boxplots representing median (ranges)
of live births in the 10 participating hospitals
from 2010 to 2017 with (A) GA < 25.0 weeks:
28 (10–72), (B) GA 25–<28.0 weeks: 238 (115–
412) and (C) GA 28.0–<32.0 weeks: 749 (380–
1156).
Table 2. Risk factors of the overall group of infants treated for ROP between 2010 and 2017,











Obstetric characteristics and interventions (n, %)
Prenatal glucocorticoids 35 (72.9%) 90 (69.2%) 11 (64.7%) 0.650*
Multiple birth 18 (33.3%) 58 (43.6%) 11 (61.1%) 0.195*
Infant characteristics (mean (SD))
GA in weeks 25.9 (1.7) 26.0 (1.7) 26.4 (1.9) 0.711†
Mean (SD) BW in grams 791 (311) 764 (204) 827 (233) 0.967†
Female gender n (%) 28 (49.1%) 67 (48.2%) 11 (57.9%) 0.844*
Neonatal morbidity (n, %)
Sepsis 35 (64.8%) 89 (66.4%) 13 (72.2%) 0.834*
IVH/PVL 29 (50.9%) 57 (41,0%) 6 (33.3%) 0.659*
Patent ductus arteriosus 44 (83.0%) 108 (81.2%) 16 (88.9%) 0.772*
IRDS 51 (89.5%) 129 (96.3%) 16 (88.9%) 0.575*
BPD 44 (77.2%) 105 (79.5%) 13 (72.2%) 0.764*
NEC 4 (7.0%) 15 (11.3%) 4 (22.2%) 0.427*
Hyperglycaemia (>8 mmol/l) 21 (36.8%) 52 (39.7%) 7 (38.9%) 0.993*
TTTS 2 (3.8%) 9 (7.1%) 1 (5.6%) 0.627*
Neonatal Interventions (n, %)
NICU admission >28 days 47 (100%) 120 (96.0%) 16 (100%) 0.325†
MV >7 days 40 (87.0%) 109 (84.5%) 13 (76.5%) 0.687*
Oxygen administration >28 days 35 (76.1%) 109 (85.8%) 12 (70.6%) 0.217*
Packed cells 51 (98.1%) 122 (93.9%) 16 (88.9%) 0.398‡
Hypotension treated
with inotropic agents
21 (36.8%) 37 (26.6%) 7 (38.9%) 0.124*
iNO 7 (13.4%) 20 (15.5%) 2 (11.8%) 0.945*
Postnatal glucocorticoids 33 (66.6%) 72 (55.0%) 6 (37.5%) 0.221*
BPD = bronchopulmonary disease, BW = birth weight, GA = gestational age, iNO = inhaled
nitric oxygen, IRDS = infant respiratory distress syndrome, IVH = intraventricular haemorrhage,
MV = mechanical ventilation, NEC = necrotizing enterocolitis, NICU = neonatal intensive care
unit, RD = retinal detachment, TTTS = twin-to-twin transfusion syndrome.
* Pearson’s Chi-Square Test.
† Mann–Whitney U-test.
‡ Fischer’s Exact Test.
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by the two-phased pathogenesis (Hell-
strom et al. 2013; Stahl & Gopel 2015;
Askie et al. 2017). During the first, so
called vaso-obliterative phase, a rela-
tively hyperoxic extrauterine
environment suppresses the release of
angiogenic factors, that is, vascular
endothelial growth factor (VEGF),
which are crucial for normal vessel
development. Moreover, oxidative
stress leads to obliteration of yet formed
vessels (Sapieha et al. 2010; Kim et al.
2016). This process is enhanced by even
higher O2 levels. Subsequently the sec-
ond, vaso-proliferative phase initiates
usually around the post-menstrual age
(PMA) of 32.0 weeks. In this phase,
poorly developed and obliterated blood
vessels are unable to meet the increasing
metabolic activity (and oxygen
demand) of the thriving neuroretina.
In turn, local areas of ischaemia stim-
ulate compensatory vessel growth by
releasing large amounts of angiogenic
factors. In case of severe ROP, how-
ever, poor quality neovascularizations
develop with a tendency to leak and
bleed with a high risk of retinal detach-
ment through fibrous traction (Hartnett
2010; Sola & Zuluaga 2013). Therefore,
it is hypothesized that the adoption of
even higher SaO2 targets in the first
phase increases the risk for the devel-
opment of treatment demanding ROP.
Potentially, this could have resulted in
more frequent progression into type I
treatment requiring ROP in period 2;
however, more detailed data are
required to confirm this hypothesis.
Third, a new Dutch ROP guideline
was implemented in 2013. The primary





ETROP type I 34 (59.6) 116 (83.5)
Zone Stage Plus
I 3 + - 4 (2.9)
II 3 + 18 (31.6) 68 (48.9)
I 2 + 1 (1.8) 2 (1.4)
II 2 + 15 (26.3) 42 (30.2)
ETROP type II 1 (1.8) 3 (2.1)
II 3 - 1 (1.8) 3 (2.1)
No ETROP 22 (38.6) 20 (14.4)
II 2 - - 2 (1.4)
II 1 + 1 (1.8) -
III 3 + 2 (3.5) 2 (1.4)
III 3 - - 1 (0.7)
III 2 + 5 (8.8) 5 (3.6)
III 1 + - 1 (0.7)
Ns 3 + 6 (10.5) 2 (1.4)
Ns 3 - 1 (1.8) -
Ns 2 + 1 (1.8) -
Na 4a + - 1 (0.7)
Na 4b + - 1 (0.7)
Ns Ns Ns 6 (10.5) 5 (3.6)
ETROP = early treatment for ROP criteria, na = not applicable, ns = not specified.
Table 4. Treatment characteristics in infants treated for ROP in Periods 1 and 2 and in those who











Age at treatment (mean (SD))
PMA at first detection of ROP 34.2  2.2 34.2  2.3 34.5  2.1 0.941*
PMA at treatment decision 36.6  2.3 36.7  2.5 36.3  2.1 0.680*
PMA at first treatment 37.8  2.3 37.3  3.3 39.1  7.2 0.791*
PNA at first treatment 12.0  3.8 11.5  3.2 12.9  6.6 0.790*
Primary treatment (n, %)
Laser 56 (98%) 134 (96%) 18 (95%)
Bevacizumab 1 (2%) 5 (4%) 1 (5%)
First recurrence (n, %) 10 (17.5) 22 (15.8) 17 (89.5) 0.390†
Unilateral additional laser 3 2 1
Bilateral additional laser 3 8 4
Unilateral TPPV 1 5 4
Bilateral TPPV 2 2 5
Unilateral IVI Bevacizumab 0 2 2
Bilateral IVI Bevacizumab 1 3 1
Second Recurrence (n, %) 3 (5.2) 9 (6.5) 11 (57.9) 0.598†
Unilateral additional laser 1 1
Bilateral additional laser 1 1
Unilateral TPPV 2 4 6
Bilateral TPPV 1 3 3
Infants with retinal detachment (n, %) 6 (10.5) 13 (9.4) - 0.791†
Bilateral 2 6 8 0.599†
IVI = intravitreal injection, PMA = post-menstrual age, PNA = postnatal age, RD = retinal
detachment, TPPV = trans pars plana vitrectomy.
* Mann–Whitney U-test.




























Fig. 3. Boxplots representing median (range)
of (A) treatments: 19 (5–29), (B) retreatments:
3 (1–6) and (C) retinal detachment: 1.5 (1–4) in




goal of the 2013 guideline was to reduce
the number to be screened, while no
severe ROP would be missed. This
measure however only regards infants
with no or mild ROP, thus, a direct
influence on the present population is
not expected. More important for our
inventory, the 2013 guideline empha-
sized the ETROP criteria. This is the
first study since 2009 to investigate the
extent of the nationwide ETROP imple-
mentation. We found an improved
documentation, suggesting better
awareness of plus disease: the percent-
age of infants that could not be catego-
rized into type 1 or type 2 decreased
from 38.6% (22/57) in period 1 to
14.4% (20/139) in period 2. However,
not only did the percentage of infants
with high ROP stages (3 or more) at
treatment decision not decrease as
expected when earlier treatment is per-
formed, it slightly increased from
49.1% to 57.6%. Moreover, the age at
treatment decision was nearly identical
(Table 4), while the age at treatment
was (not significantly) higher in the
group that developed retinal detach-
ment, suggesting that some infants in
the RD group were treated relatively
late. Internationally, there is debate
about treating ROP stage 2+ in zone
II. Within the ETROP cohort, 75.6% of
infants had stage ≥3 at treatment deci-
sion (Good 2004). Also in studies from
other countries in which the ETROP
criteria are used, the percentage of
infants with stage ≥3 ROP is high:
93.2% in Germany, where ROP stage
2+ in zone II is not listed as treatment
indication and 97.5% in Sweden, where
only ROP stages 3–5 are considered
severe (Holmstrom et al. 2016; Walz
et al. 2016). In addition, these invento-
ries showed higher retreatment num-
bers; 31.1% and 19% respectively
versus 16.3% in the present study.
Finally, even after excluding those
infants from our cohort that were
treated for stage 2+ ROP in zone II,
the increase in treatment remains anal-
ogous (Table 3). Our inventory implies
that though awareness of the ETROP
criteria improved in the Netherlands,
attention to timely treatment should
still be stressed.
Furthermore, differences were
observed between the participating
hospitals in birth rates, treatment,
retreatment numbers and outcomes
(Figs 2 and 3). As expected, higher
treatment and retreatment rates were
found in centres in which more extre-
mely premature infants were born.
Other possible explanations for the
variation could lie in different neonatal
policies, the availability of an experi-
enced surgical team or easy accessibil-
ity to a treatment centre.
Finally, six infants were primarily
treated with intravitreal Bevacizumab
(IVB), an agent antagonizing VEGF.
Mintz-Hittner et al. (2011) demon-
strated that compared to laser, IVB is
solely favourable in zone I ROP. There-
fore, the current Dutch guideline (2013)
advises the use of anti-VEGF, only as
treatment for ROP in zone I and as a
last resort. In the present study, the
number of infants with ROP in zone I is
low (Table 3), which can be explained
by the age restriction of 24.0 weeks for
active neonatal treatment. For
unknown reasons, all infants treated
with anti-VEGF agents were diagnosed
with ROP in zone II. Moreover, inci-
dence of progression to retinal detach-
ment was slightly higher to that of the
laser-treated group, which might indi-
cate that these infants had a bad prog-
nosis and anti VEGF was given as last
resort treatment. There are some limi-
tations to our study. First, due to the
retrospective setup, a limited set of data
was available. For example, details
about oxygen saturation levels and
iNO treatment were unknown, which
could have provided more opportuni-
ties for in-depth analyses. Furthermore,
as no prospective registry of infants
with ROP exists in the Netherlands, the
incidence of severe ROP in the overall
ROP population remains unknown. In
the future, a national prospective study
could give rise to more well-founded
conclusions in these matters.
To conclude, since the implementa-
tion of the new ROP guideline twice as
many infants were treated for ROP.
Reasons for this increase include a
larger population at risk, unfavorable
oxygen regime and better awareness of
screening logistics and treatment. The
corresponding increase of infants devel-
oping end-stage ROP suggests room for
even more attention to the treatment
criteria.
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